Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12518496 | 0.92 | KDM4C (0.40) | KDM4CGSK3BHDAC1HDAC6ADORA3 | |
| SCHEMBL10063378 | 0.90 | KDM4C (0.35) | KDM4CGSK3BHDAC1HDAC6ADORA3 | |
| SCHEMBL25612307 | 0.89 | HDAC6 (0.39) | KDM4CGSK3BHDAC1HDAC6ADORA3 | |
| SCHEMBL25612300 | 0.88 | HDAC6 (0.40) | KDM4CGSK3BHDAC1HDAC6ADORA3 | |
| SCHEMBL14367912 | 0.87 | KDM4C (0.34) | KDM4C | |
| SCHEMBL18625282 | 0.86 | KDM4C (0.35) | KDM4CCA12CA1CA2CA9 | |
| SCHEMBL16602269 | 0.84 | KDM4C (0.32) | KDM4C | |
| SCHEMBL10110874 | 0.82 | KDM4C (0.31) | KDM4C | |
| SCHEMBL16522851 | 0.82 | — | — | |
| SCHEMBL19771793 | 0.81 | KDM4C (0.35) | KDM4CGSK3BHDAC1HDAC6ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130142734-A1 | TARGETED DELIVERY SYSTEMS FOR DIAGNOSTIC APPLICATIONS | DAVID AYELET (IL) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142734-A1 | TARGETED DELIVERY SYSTEMS FOR DIAGNOSTIC APPLICATIONS | FCGR2A, FCER2, FCGR1A | KDM4C 3504/4885GSK3B 4861/4885HDAC1 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.